Abstract
Inflammatory responses in all tissue compartments require the emigration of leukocytes from the microvasculature through endothelial cells into the respective microenvironment. Adhesion to endothelial cells is the most crucial step in order to facilitate selective and effective capture of leukocytes. The sequence of adhesions events, e.g. rolling, tethering, and firm adhesion are tightly regulated by a variety of molecules expressed by endothelial cells and leukocytes either constitutively or after induction by mainly inflammatory mediators. In diseases with a prominent inflammatory response such as psoriasis, rheumatoid arthritis, or Crohn ’ s disease, interference with leukocyte adhesion and/or emigration may be of substantial clinical effect. A number of therapeutic approaches by using monoclonal antibodies, designed molecules, and other modulators of adhesion molecule expression have been investigated in clinical trials. This review aims to give an overview about the current knowledge of targeting adhesion molecules as a therapeutic strategy to treat inflammatory diseases.
Keywords: leukocyte function-associated antigen 1 (LFA-1), ICAM-1, Efomycines, Glucocorticoids, immune disorders
Current Pharmaceutical Design
Title: Leukocyte Adhesion: A Suitable Target for Anti-Inflammatory Drugs
Volume: 12 Issue: 22
Author(s): Ulrich Mrowietz and Wolf-Henning Boehncke
Affiliation:
Keywords: leukocyte function-associated antigen 1 (LFA-1), ICAM-1, Efomycines, Glucocorticoids, immune disorders
Abstract: Inflammatory responses in all tissue compartments require the emigration of leukocytes from the microvasculature through endothelial cells into the respective microenvironment. Adhesion to endothelial cells is the most crucial step in order to facilitate selective and effective capture of leukocytes. The sequence of adhesions events, e.g. rolling, tethering, and firm adhesion are tightly regulated by a variety of molecules expressed by endothelial cells and leukocytes either constitutively or after induction by mainly inflammatory mediators. In diseases with a prominent inflammatory response such as psoriasis, rheumatoid arthritis, or Crohn ’ s disease, interference with leukocyte adhesion and/or emigration may be of substantial clinical effect. A number of therapeutic approaches by using monoclonal antibodies, designed molecules, and other modulators of adhesion molecule expression have been investigated in clinical trials. This review aims to give an overview about the current knowledge of targeting adhesion molecules as a therapeutic strategy to treat inflammatory diseases.
Export Options
About this article
Cite this article as:
Mrowietz Ulrich and Boehncke Wolf-Henning, Leukocyte Adhesion: A Suitable Target for Anti-Inflammatory Drugs, Current Pharmaceutical Design 2006; 12 (22) . https://dx.doi.org/10.2174/138161206777947768
DOI https://dx.doi.org/10.2174/138161206777947768 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Antiviral Nucleoside Prodrugs Await Application
Current Medicinal Chemistry Concurrence of Talaromycosis and Kaposi Sarcoma in an HIV-Infected Patient: A Case Report
Current HIV Research The Neurovascular Unit: Focus on the Regulation of Arterial Smooth Muscle Cells
Current Neurovascular Research Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Anti-Inflammatory Effects of Triterpenoids; Naturally Occurring and Synthetic Agents
Mini-Reviews in Organic Chemistry New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Retracted: Tocotrienols and its Role in Cardiovascular Health- a Lead for Drug Design
Current Pharmaceutical Design Leukocytoclastic Vasculitis Associated with HHV6-A/ciHHV6-A and HHV6-B Coinfection in an Immunocompetent Woman
Endocrine, Metabolic & Immune Disorders - Drug Targets Autoimmunity-Inducing Metals (Hg, Au and Ag) Modulate Mast Cell Signaling, Function and Survival
Current Pharmaceutical Design Caffeic Acid Phenethyl Ester (CAPE), Active Phenolic Compound of Propolis Attenuates Endothelin, Prostaglandin F2α and U46619 Elicited Contractions of Isolated Human Umbilical Artery
Current Traditional Medicine Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases
Current Pharmaceutical Design The Neuroprotective Role of PEDF: Implication for the Therapy of Neurological Disorders
Current Molecular Medicine Diversity of Human Immune System Multigene Families and its Implication in the Genetic Background of Rheumatic Diseases
Current Medicinal Chemistry Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology HCV and Autoimmunity
Current Pharmaceutical Design Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Allopurinol Hypersensitivity Reactions: Desensitization Strategies and New Therapeutic Alternative Molecules
Inflammation & Allergy - Drug Targets (Discontinued)